Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 98 peer-reviewed journal articles Updated
Endocrinology · ACTH-producing pancreatic neuroendocrine tumor

Pancreatic ACTH-producing Neuroendocrine Tumor: A Patient Guide

At a Glance

These rare pancreatic tumors make ACTH, driving dangerous cortisol excess. Treatment often starts with urgent control of cortisol and related problems such as high blood pressure, diabetes, low potassium, infections, and blood clots, followed by individualized tumor treatment.

How to Use This Guide: An ACTH-producing pancreatic neuroendocrine tumor is exceptionally rare. This guide is an overview and not a substitute for your treating team. The urgency of care depends on your current symptoms, laboratory results, tumor stage, and treatment status.

An ACTH-producing pancreatic neuroendocrine tumor (pNET) is an exceptionally rare condition where a tumor in the pancreas begins to produce ACTH (adrenocorticotropic hormone) [1][2]. ACTH is normally produced mainly by corticotroph cells in the brain’s pituitary gland. Because this hormone is produced “ectopically”—meaning outside of its usual location—it bypasses the body’s natural signaling system and relentlessly tells the adrenal glands to flood the bloodstream with cortisol [3][4]. This state of extreme hormone excess, known as ectopic Cushing syndrome, can transform a rare cancer diagnosis into a complex medical crisis that affects nearly every system in the body [2][5].

The biological impact of this hormone flood is profound and can be far more aggressive than more common forms of Cushing syndrome. Instead of a slow change in appearance, patients with an ACTH-producing pNET may experience rapid metabolic shifts characterized by dangerously high blood pressure, new or worsening diabetes, and a severe drop in potassium that can affect the heart’s rhythm [2][6]. This sudden chemical shift can also weaken the immune system, making the body vulnerable to ordinary and unusual infections, and increase the risk of dangerous blood clots [7][8]. Because the cortisol rises so rapidly, the body may not have time to develop classic physical signs like a rounded “moon face,” but may instead suffer from rapid muscle wasting and extreme physical weakness [9][2].

Managing this condition is a two-front battle that requires a highly specialized multidisciplinary team of endocrinologists, oncologists, and surgeons [10][11]. In many cases, particularly when symptoms are severe, the most urgent priority is stabilizing the life-threatening hormone levels [12][13]. Doctors often use powerful “blockade” medications to lower cortisol levels and treat metabolic complications before it is safe to proceed with tumor-directed therapies like surgery or chemotherapy [14][10]. This stabilization period is a critical first step in reducing the risks of treatment.

While the diagnosis is overwhelming, the goal of modern care is to bring the hormone levels back into balance and then address the tumor itself through precise, targeted treatments [14]. By coordinating endocrine stabilization with advanced oncology, your medical team works to resolve the immediate crisis while building a long-term plan—whether that means pursuing a cure through surgery or managing the disease long-term—to restore your safety and strength.

In this guide

6 chapters

01

Managing the Crisis of Ectopic Cushing Syndrome

Learn how a pancreatic ACTH-producing tumor causes ectopic Cushing syndrome, the emergency warning signs to watch for, and how doctors rapidly lower cortisol.

02

The Cortisol Crisis: Recognizing Rapid-Onset Symptoms

Learn how ACTH-producing pancreatic neuroendocrine tumors quickly cause Cushing syndrome, with severe weakness, low potassium, diabetes, and high blood pressure.

03

Proving the Source: Tests, Scans, and Your Pathology Report

Learn how doctors confirm a pancreatic ACTH-producing neuroendocrine tumor, interpret cortisol tests and scans, and understand Ki-67, grade, and pathology results.

04

Taming the Storm: Medical Control of Cortisol

Learn how ACTH-producing pancreatic neuroendocrine tumors cause cortisol excess and how medicines, monitoring, etomidate, and adrenalectomy can reduce risks.

05

Treating the Tumor: Surgery, Radiation, and Oncology

Learn how ACTH-producing pancreatic neuroendocrine tumors are treated, including surgery, SSAs, PRRT, CAPTEM, chemotherapy, and hormonal-flare safety.

06

Survivorship: Healing After Cortisol Excess

Learn about recovery after an ACTH-producing pancreatic neuroendocrine tumor, including surveillance, adrenal function, bone health, diabetes, and digestion.

Common questions in this guide

What is an ACTH-producing pancreatic neuroendocrine tumor?
It is a rare tumor in the pancreas that makes ACTH, a hormone normally produced mainly by the pituitary gland. The extra ACTH tells the adrenal glands to release too much cortisol, causing a condition called ectopic Cushing syndrome.
Why does this tumor require urgent attention?
Cortisol can rise quickly and cause dangerously high blood pressure, new or worsening diabetes, low potassium, severe weakness, infections, and blood clots. Low potassium can also disturb the heart’s rhythm, so your team may need to stabilize hormone and metabolic problems promptly.
Which specialists usually manage this condition?
Care often involves an endocrinologist to control ACTH and cortisol, an oncologist to plan tumor treatment, and a surgeon to assess whether the tumor can be removed. These specialists may coordinate through a multidisciplinary team, especially when hormone complications are severe.
Will doctors treat high cortisol before treating the tumor?
Often, yes. If cortisol excess is severe, doctors may first use cortisol-lowering medicines and treat problems such as high blood pressure, diabetes, or low potassium before surgery or chemotherapy is safe. The order depends on your symptoms, laboratory results, tumor stage, and overall treatment plan.
Can an ACTH-producing pancreatic neuroendocrine tumor be removed with surgery?
Some patients may be candidates for surgical removal, but the decision depends on the tumor’s classification and stage, your symptoms, and whether hormone and metabolic problems are controlled. When immediate surgery is not appropriate, the team may focus first on hormone control and other tumor-directed treatment.
What is the difference between a well-differentiated tumor and a poorly differentiated neuroendocrine carcinoma?
These are different tumor categories with different expected behavior and treatment approaches. Your oncology team can explain how the classification affects the urgency and sequence of hormone stabilization, surgery, chemotherapy, or other care.

Get notified when new evidence is published on pancreatic ACTH-producing neuroendocrine tumor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (14)
  1. 1

    ECTOPIC CUSHING SYNDROME: A 10-YEAR EXPERIENCE FROM A TERTIARY CARE CENTER IN SOUTHERN INDIA.

    Sathyakumar S, Paul TV, Asha HS, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2017; (23(8)):907-914 doi:10.4158/EP161677.OR.

    PMID: 28614007
  2. 2

    Adrenocorticotropic Hormone-Producing Pancreatic Neuroendocrine Neoplasms: A Systematic Review.

    Wu Y, Xiong G, Zhang H, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2021; (27(2)):152-157 doi:10.1016/j.eprac.2020.10.012.

    PMID: 33616046
  3. 3

    Successful percutaneous CT-guided microwave ablation of adrenal gland for ectopic Cushing syndrome.

    Zener R, Zaleski A, Van Uum SH, et al.

    Clinical imaging 2017; (42()):93-95 doi:10.1016/j.clinimag.2016.11.021.

    PMID: 27919009
  4. 4

    Ectopic Cushing syndrome caused by a pancreatic neuroendocrine tumor: A case report.

    Shayesteh S, Fouladi DF, Fishman EK, Kawamoto S

    Radiology case reports 2020; (15(7)):1014-1017 doi:10.1016/j.radcr.2020.04.009.

    PMID: 32547669
  5. 5

    Pulmonary embolism as the presenting symptom and a confounder in ACTH-secreting bronchial carcinoid

    Yang W, Pham D, Vierra AT, et al.

    Endocrinology, diabetes & metabolism case reports 2019; (2019(1)) doi:10.1530/EDM-19-0033.

    PMID: 31352698
  6. 6

    Pseudo Primary Aldosteronism as Initial Presentation of Ectopic ACTH Syndrome in Metastatic Small Cell Lung Cancer.

    Shakesprere J, El Naili R, Sadiq M, Haider A

    JCEM case reports 2023; (1(1)):luac020 doi:10.1210/jcemcr/luac020.

    PMID: 37908248
  7. 7

    [Infectious pneumonia favored by paraneoplastic Cushing syndrome in a pulmonary carcinoid tumor].

    Hindré R, Poté N, Mordant P, Le Guen P

    Revue des maladies respiratoires 2023; (40(8)):716-722 doi:10.1016/j.rmr.2023.06.007.

    PMID: 37633811
  8. 8

    Adrenocorticotropic hormone-secreting pancreatic neuroendocrine carcinoma with multiple organ infections and widespread thrombosis: A case report.

    Yoshihara A, Nishihama K, Inoue C, et al.

    World journal of clinical cases 2022; (10(17)):5723-5731 doi:10.12998/wjcc.v10.i17.5723.

    PMID: 35979125
  9. 9

    Cushing´s syndrome: Clinical presentation and associated comorbidities.

    Lomba AA, Salazar-Solarte AM, Vernaza Trujillo DA, Rivera-Martínez WA

    Vitamins and hormones 2026; (132()):1-55 doi:10.1016/bs.vh.2026.04.001.

    PMID: 42236005
  10. 10

    Update in the Management of ACTH-Secreting Gastroenteropancreatic and Thoracic Neuroendocrine Neoplasms.

    Tsoli M, Bel-Ange A, Atlan K, et al.

    Current treatment options in oncology 2025; (26(11)):1010-1022 doi:10.1007/s11864-025-01354-0.

    PMID: 41042443
  11. 11

    Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.

    Del Rivero J, Perez K, Kennedy EB, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023; (41(32)):5049-5067 doi:10.1200/JCO.23.01529.

    PMID: 37774329
  12. 12

    Therapeutic Strategies for the Treatment of Severe Cushing's Syndrome.

    Alexandraki KI, Grossman AB

    Drugs 2016; (76(4)):447-58 doi:10.1007/s40265-016-0539-6.

    PMID: 26833215
  13. 13

    Medical therapy in severe hypercortisolism.

    Marques JVO, Boguszewski CL

    Best practice & research. Clinical endocrinology & metabolism 2021; (35(2)):101487 doi:10.1016/j.beem.2021.101487.

    PMID: 33518458
  14. 14

    MANAGEMENT OF ENDOCRINE DISEASE: Cushing's syndrome due to ectopic ACTH secretion: an expert operational opinion.

    Young J, Haissaguerre M, Viera-Pinto O, et al.

    European journal of endocrinology 2020; (182(4)):R29-R58.

    PMID: 31999619

This page is for informational purposes only and does not constitute medical advice. Because ACTH-producing pancreatic neuroendocrine tumors can cause rapidly dangerous cortisol excess, discuss urgent monitoring and treatment with your endocrinology and oncology team.